These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10883417)

  • 1. Pharmacokinetic/pharmacodynamic evaluation of a novel potassium channel opener, SKP-450, in healthy volunteers.
    Jang IJ; Yu KS; Shon JH; Bae KS; Cho JY; Yi SY; Shin SG; Ryu KH; Cho YB; Kim DK; Yoo SE
    J Clin Pharmacol; 2000 Jul; 40(7):752-61. PubMed ID: 10883417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
    Shin HS; Seo HW; Oh JH; Lee BH
    Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers.
    Uematsu T; Kosuge K; Hirosawa S; Kadobe Y; Hibi T; Nakashima M
    J Clin Pharmacol; 1996 May; 36(5):439-51. PubMed ID: 8739023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic profile of SKP-450, a new potassium-channel activator.
    Lee BH; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1998 Jan; 31(1):85-94. PubMed ID: 9456282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular pharmacology of SKP-450, a new potassium channel activator, and its major metabolites SKP-818 and SKP-310.
    Shin HS; Seo HW; Yoo SE; Lee BH
    Pharmacology; 1998 Mar; 56(3):111-24. PubMed ID: 9532610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
    Yu KS; Bae KS; Shon JH; Cho JY; Yi SY; Chung JY; Lim HS; Jang IJ; Shin SG; Song KS; Moon BS
    J Clin Pharmacol; 2004 Jan; 44(1):73-82. PubMed ID: 14681344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
    Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profiles of SKP-450 and its family, a K+ channel opener, in comparison with levcromakalim.
    Hong KW; Shin HS; Kim CD; Shin YW; Yoo Se
    Pharmacol Res; 1998 Sep; 38(3):191-7. PubMed ID: 9782069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study.
    Gu N; Kim J; Lim KS; Shin KH; Kim TE; Lee B; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Sep; 34(9):1929-39. PubMed ID: 22921287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
    Lee YM; Yen MH; Peng YY; Sheu JR; Chen YC; Chang MJ; Cheng CY
    Eur J Pharmacol; 2000 May; 397(1):151-60. PubMed ID: 10844109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans.
    Senior R; Buchner-Moell D; Raftery E; Lahiri A
    J Cardiovasc Pharmacol; 1993 Nov; 22(5):717-21. PubMed ID: 7506324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
    Sardina M; Warrington SJ; Boyce M; Johnston A; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S80-90. PubMed ID: 8839231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and pharmacokinetics of a new P-glycoprotein inhibitor, HM30181, in healthy Korean male volunteers: single- and multiple-dose randomized, placebo-controlled studies.
    Kim TE; Gu N; Yoon SH; Cho JY; Park KM; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Feb; 34(2):482-94. PubMed ID: 22284902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.
    Hagmann M; Nussberger J; Naudin RB; Burns TS; Karim A; Waeber B; Brunner HR
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):444-50. PubMed ID: 9156352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH; Sioufi A; Preiswerk G; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J; Pérez O; Delpón E; García-Rafanell J; Gómez L; Cavalcanti F
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):295-305. PubMed ID: 7475055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus.
    Zhao C; Vaidyanathan S; Yeh CM; Maboudian M; Armin Dieterich H
    Clin Pharmacokinet; 2006; 45(11):1125-34. PubMed ID: 17048976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.